Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Illumina launched its TruSight One sequencing panel, which targets 4,813 genes with known associated clinical phenotypes. Clinical research laboratories can use this panel to expand existing menus, streamline workflows, or create an entire portfolio of sequencing options, with benefits including increased productivity, reduced handling errors, and decreased costs.
NanoString Technologies has received FDA 510(k) clearance for its Prosigna breast cancer prognostic gene signature assay. Based on the PAM50 gene signature, Prosigna is the company’s first FDA-cleared in vitro diagnostic assay and uses the gene-expression profile of cells found in breast cancer tissue to assess a patient’s risk of distant recurrence of disease. The Prosigna assay is performed using the nCounter Dx analy
Air Science’s Purair Bio safety cabinet is designed to protect individuals, the environment, and products from a variety of biological particulates, serving as the primary barrier in life science research and experimentation.
Terumo BCT has received FDA 510(k) clearance for single-needle therapeutic plasma exchange (SN-TPE) on its Spectra Optia apheresis system. This option gives therapeutic apheresis operators the ability to convert to SN-TPE at the beginning or at any time during the procedure, depending on patient needs.
Bleach-Rite Spray, manufactured by Current Technologies, has been approved by the EPA to kill Clostridium difficile spores on hard, nonporous surfaces in five-minute contact time. Bleach-Rite is a hospital-grade spray disinfectant/cleaner, ready to use at the 1:10 dilution recommended by the CDC, OSHA, and NCCLS. The solution is stabilized for an extended shelf life with an expiration date on every bottle.
Ventana Medical Systems and Boehringer Ingelheim have entered into an agreement to collaborate on the development of companion diagnostic tests for Boehringer Ingelheim oncology programs.
Hemo Bioscience and Ortho Clinical Diagnostics have developed an exclusive arrangement for distribution of two new HBS products.
Clean Collect blood culture kits, available from Stone Medical, prevent contamination of blood cultures using a patented diversion method.
SciGene’s new sodium thiocyanate pretreatment reagent, a convenient 1-M liquid formulation of NaSCN for pretreating tissue samples prior to application of nucleic acid probes for cytogenetic assays, joins an expanding line of FISH slide-processing products from SciGene.
Smart Imaging Technologies’ Interactive Web Reports for its Simagis Live Digital Pathology servers make it possible for pathologists to complete and sign off digital cases, create professional, media-rich reports from digital slides, and share them instantly with clients, colleagues, or patients.
